What is HC Wainwright’s Estimate for IO Biotech Q1 Earnings?

IO Biotech, Inc. (NASDAQ:IOBT) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for IO Biotech in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.50) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for IO Biotech’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for IO Biotech’s Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.42) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.91) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.39) EPS, FY2028 earnings at ($0.39) EPS, FY2029 earnings at ($0.13) EPS and FY2029 earnings at ($0.13) EPS.

Separately, Piper Sandler raised shares of IO Biotech to a “strong-buy” rating in a research report on Wednesday, March 12th.

IO Biotech Trading Down 2.1 %

NASDAQ IOBT opened at $0.98 on Friday. The company has a market cap of $64.84 million, a P/E ratio of -0.72 and a beta of 0.08. IO Biotech has a 1 year low of $0.66 and a 1 year high of $1.79. The company has a fifty day simple moving average of $0.97 and a 200 day simple moving average of $0.98.

Hedge Funds Weigh In On IO Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Dauntless Investment Group LLC bought a new stake in IO Biotech in the 4th quarter valued at $688,000. Landscape Capital Management L.L.C. acquired a new position in shares of IO Biotech during the fourth quarter valued at about $407,000. Citadel Advisors LLC bought a new stake in shares of IO Biotech in the fourth quarter valued at about $249,000. Renaissance Technologies LLC grew its position in IO Biotech by 22.5% during the fourth quarter. Renaissance Technologies LLC now owns 118,800 shares of the company’s stock worth $109,000 after buying an additional 21,800 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new position in IO Biotech during the fourth quarter valued at about $30,000. Institutional investors own 54.76% of the company’s stock.

About IO Biotech

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.